<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

2 min read

COVID Applies the Brakes: Q420/FY20 Spinal Cord Stimulation Market Recap

By Anne Staylor on 3/28/21 6:21 PM

While US SCS revenues were almost back to pre-COVID levels in Q320, rising COVID case rates put the brakes on procedure growth by the end of Q420 and the US and WW SCS markets ended down -15%+ in FY20 compared to FY19.

Although spinal cord stimulation (SCS) revenues were almost back to pre-COVID levels in Q320, by the end of Q420, rising COVID case rates in certain geographies put the brakes on procedure growth, resulting in a low-single-digit (LSD) decrease in YoY revenues in both the US and WW in Q420. For the full year (FY), US SCS were down -15.1%, with revenues, according to SmartTRAK SCS Financial Dashboard, totaling ...

Among the many topics covered in the comprehensive Q420/FY20 Spinal Cord Stimulation Market Recap * are:

Continue Reading
3 min read

Abbott Launches Remote Programming for Neuromodulation: An Interview with Keith Boettiger

By Anne Staylor on 3/23/21 8:00 AM

In an interview with SmartTRAK, Keith Boettiger, VP of Abbott Neuromodulation, discusses the Company’s new NeuroSphere Virtual Clinic, a potentially game-changing technology that enables physicians to remotely program stim settings for patients with DBS, SCS and DRG devices in real-time.

On March 8, 2021, Abbott announced the US launch and FDA approval of the NeuroSphere Virtual Clinic, a first-of-its-kind remote neuromodulation patient-care technology that allows patients to receive new treatment settings from their physicians in real-time and remotely via cloud and Bluetooth-based technology. Using the patient controller app, a new remote programming feature, the clinician programming app and a new secure remote connection, physicians can communicate with patients and remotely optimize and digitally prescribe new stimulation settings for patients who are implanted with a deep brain stimulator, spinal cord stimulator or a dorsal root ganglion stimulator.

Keith Boettiger, VP of Abbott Neuromodulation, discusses remote programming using the NeuroSphere Virtual Clinic and what it means for physicians, patients and the market for neuromodulation devices in an interview with SmartTRAK. To listen to the interview, recorded recently via Uberconference, click on the following video (24:09 minutes). A link to download the transcript of the interview is also provided below.

Continue Reading
9 min read

R&D Focus on Neuromodulation: Patents, Products & Predictions

By Anne Staylor on 3/3/21 8:15 AM

Despite the continuing challenges posed by the pandemic, the MedTech industry presses on with product innovation and plans for the future. SmartTRAK reports daily on the challenges still ahead, covering all aspects of the Neuromodulation market.

The following is just a small sampling of recent Neuromodulation updates from around the world compiled, reviewed and posted in real time by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, patents, trends, new products, financial data and competitor developments in the global Life Sciences industry.

As part of SmartTRAK's R&D appreciation month, Research & Development professionals can now sign up for a Complimentary Month of Daily Updates delivered straight to your inbox. Just let us show you SmartTRAK and we'll give you a month of Daily Updates for FREE!

Continue Reading
4 min read

NANS 2021: An Interview with Boston Scientific's Nilesh Patel, MD

By Anne Staylor on 3/2/21 7:45 AM

Nilesh Patel, MD, vice president of medical affairs for Boston Scientific, discusses the Company’s latest research and innovation in neuromodulation in an interview with SmartTRAK.

With the US launch of the WaveWriter Alpha portfolio of spinal cord stimulation systems, fast-acting sub-perception therapy (FAST) and the Cognita suite of digital solutions, Boston Scientific is expanding the boundaries of pain therapy and fueling a new era of personalization using advanced analytics to identify, predict and intervene early in a patient’s pain. Nilesh Patel, MD, vice president of medical affairs at Boston Scientific (BSX), discusses these advances and more from the virtual NANS 2021 meeting in an interview with SmartTRAK.

To listen to the interview, recorded live via Uberconference, click on the following video. Read on to find out how to receive a transcript of the complete interview.

Continue Reading
3 min read

NANS 2021: An Interview with Medtronic's Charlie Covert

By Anne Staylor on 2/18/21 9:30 AM

Charlie Covert, Medtronic’s VP/GM of Pain Therapies, discusses the Company’s neuromodulation news at NANS 2021 in an interview with SmartTRAK.

To find out about what was new for MDT at NANS 2021, including the 12-month results from MDT’s DTM SCS study, its initiatives in evoked compound action potentials (ECAPs), the Vanta recharge-free SCS and MDT’s research into expanded indications, click on the following video below to listen to SmartTRAK’s interview with Charlie Covert recorded live via Uberconference (25:39 min). A complete transcript of the interview is also provided below.

Continue Reading
2 min read

A Ray of Sunshine but Dark Clouds Ahead: Q320 SCS Market Recap

By Anne Staylor on 1/4/21 10:54 AM

The US Spinal Cord Stimulation Market saw a ray of sunshine in Q320 as revenues recovered to almost pre-COVID levels, but dark clouds lie ahead

Q320 was a ray of sunshine for the US Spinal Cord Stimulation (SCS) market as revenues returned to almost pre-COVID levels according to SmartTRAK Financial Dashboard. Sequentially, US revenues bounced sharply from Q220. Although OUS revenues weren’t as sunny, WW SCS revenues recovered in Q320, jumping ~60% sequentially from Q220 revenues.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Spinal Cord Stimulation Market Recap* are:

Continue Reading
3 min read

Magstim: Opportunities in Transcranial Magnetic Stimulation: An Interview with Lothar Krinke

By Anne Staylor on 12/8/20 9:09 AM

Magstim CEO Lothar Krinke, PhD discusses Magstim and opportunities in transcranial magnetic stimulation in an interview with SmartTRAK

As a pioneer in transcranial magnetic stimulation (TMS), Magstim has been a leading supplier of transcranial magnetic stimulators for the last 30 years. Although TMS was first primarily used for research applications, it is now widely used in the clinical setting as a non-invasive therapy to treat major depressive disorder in patients who have failed medication therapy or other treatments. Magstim estimates approximately 50,000+ patients per year in the US receive TMS therapy for depression, a fraction of the five-to-six million patients who currently suffer from medication-resistant depression. 

The combined worldwide market for TMS, including the clinical and research market, is estimated at ~$200 million a year, but it is potentially a multi-billion dollar market according to Magstim CEO Lothar Krinke, PhD. To find out more about TMS and Magstim, including its recent acquisition of Electrical Geodesics (EGI) and its high-density EEG from Royal Philips, click on the following video to listen to SmartTRAK’s interview with Dr. Krinke, recorded live via Uberconference (31:05 min). To download a complete transcript of the interview, just click the link below.

Continue Reading
2 min read

Medtronic DTM SCS: Using Basic Science to Orchestrate Pain Relief

By Anne Staylor on 11/30/20 3:08 PM

Charlie Covert, VP/GM of Medtronic’s Pain Therapies business, discusses 12-month follow up data from the DTM SCS RCT, orchestrating the neuro-glial response and much more in an interview with SmartTRAK.

Charlie Covert, VP/GM of Medtronic’s Pain Therapies business discusses 12-month data from the Company’s Differential Targeted Multiplexed (DTM) SCS RCT, why they used a modified intent to treat analysis (mITT) and what’s next for DTM research in an interview with   SmartTRAK.


To find out more about DTM SCS, including its mechanism of action (MOA), how it’s doing in the market and Medtronics’ research into expanded indications and new technologies, click the link below to download the complete transcript of the interview.

Continue Reading
8 min read

PNS 2020: What’s New in Peripheral Nerve Stimulation?

By Thomas Wallick on 11/2/20 9:30 AM

In the market for Peripheral Nerve Stimulation (PNS), companies are developing new wireless or minimally invasive technologies with novel waveforms and form factors designed to treat a wide variety of applications and unmet clinical needs, including for the treatment of intractable migraines, chronic intractable postoperative pain, suprascapular neuralgia, low back pain, tibial/ankle pain, stroke rehab, overactive bladder and tibial nerve stimulation, to name a few.

Companies competing in the market for PNS include Stimwave Technologies*, Nalu Medical*, SPR Therapeutics, Bioness and Cala Health among others. To find out more about these companies and what’s new for PNS, SmartTRAK highlights market updates covering the top news, clinical studies, reimbursement and patents in PNS so far in 2020.
Continue Reading
6 min read

COVID-19 Resurgence: The Effect on Deferred Procedures

By Thomas Wallick on 10/26/20 10:30 AM

MedTech Strategist reported that In May of this year, the Deloitte Center for Health Solutions conducted "an online survey of 50 clinical and service line leaders at US provider organizations on their deferred procedures". With the return of elective procedures being integral to a comeback for the MedTech industry, the results of that survey suggest that the path to resuming these procedures is becoming more complicated.

According to the Deloitte survey, "Respondents expect the return to pre-COVID-19 productivity volumes to take two to six months, with three months the typical estimate. When asked to list their top concerns about resuming deferred procedures, providers say a second coronavirus outbreak is their biggest worry (82%)". It appears that their biggest fear, a COVID-19 resurgence, may be coming to pass.

The following is just a small sampling of recent updates regarding the Life Sciences industry's COVID-related delayed procedures and what an impact a resurgence may have. These updates are compiled, reviewed and posted in real-time by our SmartTRAK analysts, who are constantly monitoring the situation and sifting through the noise to present the most relevant news to our subscribers:

Continue Reading

    Recent Articles